Key result
Risperidone linked to neuroleptic malignant syndrome in a 14-year-old boy.
Case Report (n=1)
Highlights the importance of considering neuroleptic malignant syndrome in pediatric patients presenting with altered mental status and a history of antipsychotic use.
Warrants vigilance for neuroleptic malignant syndrome in pediatric antipsychotic use; leaves open need for systematic safety data.
Introduction: Neuroleptic malignant syndrome (NMS) is a rare but life-threatening condition induced by antipsychotic drug usage. The history of a patient presented with high fever, muscle rigidity, and loss of consciousness to the emergency service should be carefully analyzed.Case Report: A 14-year-old boy with mutism, dysphagia, loss of consciousness, and urine incontinence was presented to our emergency service. Analysis of the patient’s history revealed that he was administered risperidone (100 mg) for10 days. The boy looked sick and confused on examination. The laboratory findings were nearly normal. The patient was diagnosed with NMS and was transfered to the pediatric intensive care unit.Conclusion: NMS is a fatal clinical contidition and should be diagosed immediately. The patient’s history should be carefully analyzed. NMS should be immediately diagnosed if there is a history of antipsycotic drug usage
No takes yet. Share an insight, caveat, or question.
Balcı et al. (2015) conducted a case report in Neuroleptic malignant syndrome (n=1). Risperidone was evaluated on Diagnosis of Neuroleptic Malignant Syndrome. A 14-year-old boy developed neuroleptic malignant syndrome after being administered 100 mg of risperidone for 10 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: